Podcasts about stage iiib

In this episode of It Takes Balls, Luke Alter, an assistant state attorney and testicular cancer survivor, shares his raw, powerful story of being misled and eventually forced to fight for his life.At just 27, Luke went from grappling on the jiu-jitsu mats to confronting a swollen testicle assumed to be a sports injury. After weeks of worsening symptoms and a urologist brushing him off, he pushed for more answers, only to hear the life-altering diagnosis.What followed was a whirlwind of scans, cross-country travel, and life-changing decisions. Luke opens up about going through four rounds of EP chemo, how a delayed diagnosis led to Stage IIIB disease, and the emotional toll of facing mortality at such a young age. He talks honestly about fear, depression, hair loss, and finding light through friends, family, Reddit threads, and complete strangers who showed up when he needed it most.Luke's story is equal parts heartbreaking and inspiring, and ultimately a testament to the power of self-advocacy, community, and choosing hope when the odds feel overwhelming.Join The Ball Room:https://www.testicularcancerawarenessfoundation.org/theballroomWant to be a guest? Apply here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-submissionsFollow Testicular Cancer Awareness Foundation:⁠https://www.testescancer.orghttps://www.twitter.com/testescancer⁠⁠https://www.instagram.com/testescancerhttps://www.facebook.com/tca.orgFollow Steven Crocker: https://www.twitter.com/stevencrockerhttps://www.instagram.com/stevencrockerhttps://www.facebook.com/steven.crocker2Connect with Luke:https://www.instagram.com/lukeduke59/https://www.facebook.com/luke.altarTheme song: No Time Like Now - Tom Willner www.tomwillner.com

Emily Voreas was diagnosed at 33 with Stage IIIb breast cancer, and also carries the BRCA2 gene. Emily has a Masters in Elementary Education and currently works as a reading interventionist. In this episode she reads her poem “Where does the story end?” from the 2024 “Family” issue of Wildfire Journal. Her poem is about four generations of women and cancer. April and Emily will discuss family cancer legacies, fertility, aesthetic flat closure, and the evolving advocacy in each generation of breast cancer. More about Emily: https://www.instagram.com/flatnfierce/Purchase the “Family” issue of Wildfire Magazine: https://www.wildfirecommunity.org/shop/p/family24Buy the Wildfire book Igniting the Fire Within: Stories of Healing, Hope & Humor, Inside Today's Young Breast Cancer Community: https://www.amazon.com/dp/B0BJVJ629F?ref_=pe_3052080_397514860Get the free Wildfire “Hot Flashes” email newsletter: https://www.wildfirecommunity.org/newsletter?rq=newsletterLearn about Wildfire writing workshops: https://www.wildfirecommunity.org/workshopsShop Wildfire merch & more: https://www.wildfirecommunity.org/shop*Free* Get Wildfire and The Burn freebies here: https://www.wildfirecommunity.org/freeMore about Wildfire Magazine: https://www.wildfirecommunity.orghttps://www.instagram.com/wildfire_bc_magazine/https://www.facebook.com/wildfirecommunityInformation on submitting your story for consideration to be published in Wildfire Magazine: https://www.wildfirecommunity.org/submissions

CME credits: 0.25 Valid until: 17-04-2024 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-personalizing-treatment-in-nsclc-locally-advanced-disease-stage-iiibc/15139/ The clinical value of adding immunotherapy together with chemoradiation in locally advanced non-small cell lung cancer (NSCLC) has been evident since 2017. This concept has been extended through the emergence of key clinical trials, such as KEYNOTE-799, which includes both squamous and non-squamous subsets. In fact, the coalescence of chemoradiation and immunotherapy has begun to not only push up overall survival, but to also improve cure rates with manageable toxicity. But as the landscape rapidly changes, it becomes increasingly difficult to link evolving data to clinical practice. Join Drs. Mark Socinski and Kristin Higgins as they parse the key trials and offer insights that will help you provide better care, and possibly more hope, for your patients with locally advanced NSCLC.=

Featuring perspectives from Dr Jarushka Naidoo, including the following topics: Adjuvant and Neoadjuvant Immunotherapy Introduction (0:00) Case: A woman in her early 70s with Stage IIIB adenocarcinoma of the lung and no targetable mutations; PD-L1 22C3 TPS = 1%, intensity 2+; PD-L1 SP 142 TPS = 5%, intensity 3+ — Ranju Gupta, MD (5:45) Consolidation and Immunotherapy After Chemoradiation for Unresectable Locally Advanced Non-Small Cell Lung Cancer Case: A woman in her mid-40s with Stage IIIA NSCLC and an EGFR exon 19 mutation; PD-L1

Featuring perspectives from Dr Stephen Liu, including the following topics: Introduction (0:00) Adjuvant and Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) (1:18) Case: A man in his late 50s with metastatic NSCLC and no actionable mutations — Sandip Patel, MD (19:53) Case: A woman in her mid-60s with newly diagnosed adenocarcinoma of the lung — PD-L1 65% — Raji Shameem, MD (27:05) Case: A man in his early 70s with localized NSCLC and no actionable mutations — PD-L1 90% — Kapisthalam (KS) Kumar, MD (33:16) Case: A woman in her early 60s with extensive-stage small cell lung cancer — Ranju Gupta, MD (36:28) Thoughts for the Future: Part 1 (41:17) Case: A woman in her early 70s with Stage IIIB adenocarcinoma of the lung and an EGFR L858R tumor mutation — PD-L1 40% — Matthew Gubens, MD, MS (45:01) Thoughts for the Future: Part 2 (51:30) CME information and select publications

In this podcast episode, Jeffrey S. Weber, MD, PhD; Allison Betof Warner, MD, PhD; and Hussein Tawbi, MD, PhD, discuss recent key data on adjuvant and neoadjuvant therapy and review the latest evidence on therapies for metastatic disease.Link to full program:https://bit.ly/3ogPjMoFollow along with the downloadable slideset:https://bit.ly/2XYNIztPresenters:  Jeffrey S. Weber, MD, PhDDeputy DirectorLaura and Isaac Perlmutter Cancer CenterNYU Langone HealthProfessor of MedicineNYU Grossman School of MedicineNew York, New YorkAllison Betof Warner, MD, PhDAssistant MemberAssistant Attending PhysicianMelanoma ServiceDivision of Solid Tumor OncologyDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkHussein Tawbi, MD, PhDProfessorDepartment of Melanoma Medical OncologyThe University of Texas MD Anderson Cancer CenterHouston, Texas 

Featuring a roundtable discussion with Drs Joshua Bauml, Nathan A Pennell and Lecia V Sequist, including the following topics: Expert perspectives on new online formats of continuing medical education programs (0:00) Case: A woman in her early 80s with Stage IIIB non-small-cell lung carcinoma (NSCLC) and an EGFR exon 21 mutation — Zanetta S Lamar, MD (7:07) Clinical implications of the Phase III ADAURA trial evaluating adjuvant osimertinib for patients with completely resected Stage IB to IIIA NSCLC and an EGFR mutation (16:18) Case: A woman in her late 30s with Stage IIIB adenocarcinoma of the lung positive for ROS1 alteration and PD-L1 expression — Spencer Henick Bachow, MD (23:42) Case: A woman in her late 70s with extensive-stage small-cell lung cancer — Namrata I Peswani, MD (28:19) Case: A man in his late 70s with NSCLC who develops recurrent mediastinal disease and pleural effusion — Ranju Gupta, MD (31:02) Case: A woman in her early 60s with metastatic NSCLC and discordant BRAF mutation test results — Syed Farhan Zafar, MD (39:07) CME information and select publications

Melanoma Update, Issue 1, 2021 — Part 1: Our interview with Dr Davies highlights the following topics as well as cases from his practice: Evolving treatment approaches for regionally metastatic melanoma (0:00) Case: A man in his early 70s with a history of poorly controlled hypertension who is diagnosed with Stage IIIB melanoma with a BRAF V600E mutation (20:42) Case: A woman in her mid-20s with Stage IIIA melanoma with a BRAF V600E mutation (28:46) Case: A man in his early 30s with Stage IIIC melanoma and an NRAS Q61K mutation (37:53) Role of immunotherapy for patients with melanoma in the adjuvant setting (44:16) Adjuvant therapy with BRAF/MEK inhibitors for patients with melanoma and BRAF mutations (48:51) Design and results of the Phase III KEYNOTE-054 trial comparing pembrolizumab to placebo after complete resection of high-risk Stage III melanoma (50:58) Benefits and risks of adjuvant immunotherapy and targeted therapy (53:06) Risk of brain metastases for patients with melanoma; efficacy of nivolumab/ipilimumab in patients with brain metastases (57:16) Activity and tolerability of dabrafenib/trametinib as adjuvant therapy (1:01:38) Emerging data with targeted therapy and immunotherapy in the neoadjuvant setting (1:08:45) Role of immunotherapy and targeted therapy for mucosal and uveal melanoma; improvement in overall survival with the novel bispecific fusion protein tebentafusp for metastatic uveal melanoma (1:13:57) Efficacy of autologous tumor infiltrating lymphocytes (TILs) for patients with metastatic melanoma (1:16:54) Approach to relapse after immunotherapy or targeted therapy in the adjuvant setting (1:19:43) Emerging data from the Phase III CheckMate 915 trial of nivolumab alone or with ipilimumab for patients with resected high-risk melanoma; results of the CheckMate 067 trial of nivolumab or ipilimumab alone or in combination for advanced melanoma (1:23:15) CME information and select publications

Special Nursing Edition focused on locally advanced non-small cell lung cancer (NSCLC). This program includes case discussions from the practices of Elizabeth S Waxman, RN, MSN, ANP-BC and Beth Sandy, MSN, CRNP. Access NCPD information and select publications here. Case 1 (Elizabeth Waxman): A woman in her early 60s with Stage IIIB adenocarcinoma of the lung Case 2 (Elizabeth Waxman): A woman in her early 80s with Stage III NSCLC Case 3 (Beth Sandy): A woman in her late 60s with locally advanced NSCLC Case 4 (Beth Sandy): A woman in her early 70s with locally advanced NSCLC

Kathryn interviews Financial Advisor Steven Melen, author of “Killer Graces: My path from pain to power and breakthrough living.” In his late thirties, Steve thought he had it all — a successful career in finance, a house on the hill, a lovely and accomplished wife, a beautiful newborn daughter and a zest for life and travel. He was unstoppable ... until a diagnosis of Stage IIIB stomach cancer brought it all to screeching halt. Kathryn also interviews TV Host & Founder, EarthEcho International Philippe Cousteau, author of “The Endangereds.” The first book in a science-backed, high-action series, this adventure of a spunky group of endangered animals has an important environmental message for young audiences. Grandson of Jacques Cousteau, Philippe has hosted numerous TV programs for Discovery, BBC, CNN, Travel Channel and more. Currently he's the host of the syndicated television show Xploration Awesome Planet and producer/narrator of a new Virtual Reality experience Drop in the Ocean.

Kathryn interviews Financial Advisor Steven Melen, author of “Killer Graces: My path from pain to power and breakthrough living.” In his late thirties, Steve thought he had it all — a successful career in finance, a house on the hill, a lovely and accomplished wife, a beautiful newborn daughter and a zest for life and travel. He was unstoppable ... until a diagnosis of Stage IIIB stomach cancer brought it all to screeching halt. Kathryn also interviews TV Host & Founder, EarthEcho International Philippe Cousteau, author of “The Endangereds.” The first book in a science-backed, high-action series, this adventure of a spunky group of endangered animals has an important environmental message for young audiences. Grandson of Jacques Cousteau, Philippe has hosted numerous TV programs for Discovery, BBC, CNN, Travel Channel and more. Currently he's the host of the syndicated television show Xploration Awesome Planet and producer/narrator of a new Virtual Reality experience Drop in the Ocean.

Kathryn interviews Financial Advisor Steven Melen, author of “Killer Graces: My path from pain to power and breakthrough living.” In his late thirties, Steve thought he had it all — a successful career in finance, a house on the hill, a lovely and accomplished wife, a beautiful newborn daughter and a zest for life and travel. He was unstoppable ... until a diagnosis of Stage IIIB stomach cancer brought it all to screeching halt. Kathryn also interviews TV Host & Founder, EarthEcho International Philippe Cousteau, author of “The Endangereds.” The first book in a science-backed, high-action series, this adventure of a spunky group of endangered animals has an important environmental message for young audiences. Grandson of Jacques Cousteau, Philippe has hosted numerous TV programs for Discovery, BBC, CNN, Travel Channel and more. Currently he's the host of the syndicated television show Xploration Awesome Planet and producer/narrator of a new Virtual Reality experience Drop in the Ocean.

Kathryn interviews Financial Advisor Steven Melen, author of “Killer Graces: My path from pain to power and breakthrough living.” In his late thirties, Steve thought he had it all — a successful career in finance, a house on the hill, a lovely and accomplished wife, a beautiful newborn daughter and a zest for life and travel. He was unstoppable ... until a diagnosis of Stage IIIB stomach cancer brought it all to screeching halt. Kathryn also interviews TV Host & Founder, EarthEcho International Philippe Cousteau, author of “The Endangereds.” The first book in a science-backed, high-action series, this adventure of a spunky group of endangered animals has an important environmental message for young audiences. Grandson of Jacques Cousteau, Philippe has hosted numerous TV programs for Discovery, BBC, CNN, Travel Channel and more. Currently he's the host of the syndicated television show Xploration Awesome Planet and producer/narrator of a new Virtual Reality experience Drop in the Ocean.

Special nursing program focused on PARP inhibitors. This program includes case discussions from the practices of Deborah Wright, MSN, APRN, CNS, Jamie Carroll, APRN, MSN, CNP, Tammy Triglianos, RN, MS, ANP-BC, AOCNP and Erika Meneely, APRN, BC. Access NCPD information and select publications here. Case: A woman in her late 40s with ovarian cancer — Deborah Wright, MSN, APRN, CNS Case: A woman in her early 50s with Stage IIIB high-grade serous ovarian cancer — Ms Wright Case: A woman in her mid-50s with Stage IIIC high-grade serous ovarian cancer — Ms Wright Case: A woman in her early 40s with metastatic triple-negative breast cancer (TNBC) and a germline BRCA mutation — Jamie Carroll, APRN, MSN, CNP Case: A woman in her early 50s with ER-positive, HER2-negative breast cancer and a BRCA germline mutation — Ms Carroll Case: A woman in her late 50s with metastatic TNBC and a germline BRCA mutation — Ms Carroll Case: A man in his late 60s with metastatic pancreatic cancer — Tammy Triglianos, RN, MS, ANP-BC, AOCNP Case: A man in his late 60s with metastatic pancreatic cancer — Ms Triglianos Case: A man in his early 50s with metastatic prostate cancer — Erika Meneely, APRN, BC Case: A man in his early 60s with metastatic prostate cancer — Ms Meneely Case: A man in his early 70s with metastatic prostate cancer — Ms Meneel

Video proceedings from the fifth in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Dr Erika Hamilton, Ms Elizabeth O'Reilly, Dr Hope S Rugo and Ms Gretchen Santos: Introduction (00:00) Program overview: Dr Love HER2-Positive Localized and Metastatic Breast Cancer (BC) (2:16) Case (Ms O'Reilly): A woman in her late 40s with ER-positive, HER2-positive Stage IIIB inflammatory BC who received neoadjuvant treatment, had significant residual disease at surgery and began adjuvant T-DM1 (9:04) Case (Ms Santos): A woman in her early 60s with ER-negative, HER2-positive BC who began 1 year of adjuvant trastuzumab/pertuzumab after mastectomy but was switched to T-DM1 (12:31) Case (Ms Santos): A woman in her early 40s with ER-positive, HER2-positive BC who received postadjuvant neratinib on the CONTROL study (38:38) Case (Ms O'Reilly): A woman in her early 60s initially diagnosed with ER-positive, HER2-negative BC presents with ER-positive, HER2-positive metastatic disease to the bone, liver and brain (43:41) ER-Positive, HER2-Negative Metastatic Disease (55:50) Case (Ms Santos): A premenopausal woman in her early 50s with widespread ER/PR-positive, HER2-negative metastatic BC to the bone who underwent ovarian ablation and received palbociclib/letrozole (1:5:38) Case (Ms O'Reilly): A woman in her early 50s with ER-positive metastatic BC who received multiple lines of systemic treatment, including abemaciclib monotherapy (1:15:53) Triple-Negative Metastatic BC (1:31:31) Case (Ms Santos): A woman in her mid-30s with metastatic triple-negative BC who experienced a good response to pembrolizumab (1:37:46) Select publications

Video proceedings from the third in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Dr Edward B Garon, Dr Matthew Gubens, Ms Blanca Ledezma and Ms Wendi S Lee. Introduction (0m0s) Program overview: Dr Love Historical Treatment Paradigms and Related Outcomes for Patients with Stage III Non-Small Cell Lung Cancer (NSCLC); Biologic Rationale for the Evaluation of Immune Checkpoint Inhibitors in This Setting (00:54) Case (Ms Lee): A woman in her early 70s with Stage IIIA adenocarcinoma of the lung who received concurrent chemoradiation therapy and developed Grade 2 esophagitis (1:16) Available Efficacy Data with and Indications for Durvalumab Consolidation in Unresectable Stage III Disease (16:22) Case (Ms Ledezma): A man in his early 70s who received chemoradiation therapy and consolidation durvalumab for new primary Stage III NSCLC after undergoing treatment for Stage IIIB disease 10 years prior (16:34) Case (Ms Lee): A woman in her early 70s with Stage IIIB adenocarcinoma of the lung who underwent concurrent chemoradiation therapy followed by durvalumab consolidation (28:59) Incidence, Recognition and Management of Immune-Mediated and Other Toxicities Associated with the Use of Durvalumab in Unresectable Stage III Disease (55:03) Case (Ms Ledezma): A man in his mid-70s with Stage IIIA NSCLC who enrolled on a clinical trial of neoadjuvant atezolizumab and developed pneumonitis (1:8:31) Case (Ms Ledezma): A woman in her early 50s who was found to have a Stage III adenocarcinoma of the lung with an EGFR tumor mutation while undergoing workup for breast cancer and received chemoradiation therapy and durvalumab consolidation (1:13:58) Case (Ms Lee): A man in his 50s with Stage IIIA adenocarcinoma of the lung who received chemoradiation therapy and consolidation durvalumab after undergoing lobectomy (1:17:10) Select publications

Lung Cancer for Radiation Oncologists — Part 1: Our interview with Dr Rimner highlights the following topics and cases from his practice: Evaluation, staging and typical disease management approaches for patients with locally advanced non-small cell lung cancer (NSCLC) (00:00) Selection and dose of postoperative radiation therapy (RT) (3:34) Stereotactic body RT (SBRT) versus surgery for patients with early-stage NSCLC (8:57) Case: A man in his mid-70s, a former smoker, with Stage IIIC adenocarcinoma of the lung receives durvalumab consolidation after chemoradiation therapy (CRT) (11:52) Optimal design of the radiation treatment field; mitigation of RT-associated side effects (14:05) Results of the Phase III RTOG-0617 trial evaluating carboplatin/paclitaxel in combination with standard- versus high-dose conformal RT, with or without cetuximab, for Stage III NSCLC (18:19) Role of RT in enhancing tumor immunogenicity (22:47) Avoiding safety concerns with the combination of CRT and immune checkpoint inhibitors (26:41) Activity and tolerability of pembrolizumab after RT in patients with NSCLC on the Phase I KEYNOTE-001 trial (29:09) PACIFIC trial: Efficacy and tolerability of durvalumab after CRT for patients with unresectable Stage III NSCLC (31:00) Activity of durvalumab after CRT; diagnosis and management of pneumonitis associated with durvalumab/CRT (36:14) Ongoing Phase II trial evaluating the activity and safety of nintedanib with prednisone for the treatment of radiation pneumonitis (39:51) Incidence of pneumonitis with CRT alone and with the addition of durvalumab (43:19) Survival outcomes and duration of consolidation therapy with durvalumab (44:33) Ongoing evaluation of immune checkpoint inhibitors with concurrent RT with or without chemotherapy (47:53) Activity of immune checkpoint inhibitors in the neoadjuvant setting (50:04) Selection of the optimal dose and technique of RT for locally advanced NSCLC (51:57) Case: A woman in her early 70s with unresectable Stage IIIB adenocarcinoma of the lung and a KRAS mutation receives CRT followed by durvalumab (56:12) Clinical experience with the use of durvalumab after CRT (58:44) Case: A woman in her mid-50s with Stage III adenocarcinoma of the lung and an EGFR mutation receives adjuvant osimertinib (1:1:44) Increased RT precision with the merging of MRI and a linear accelerator (1:5:46)  Select publications

How One Person Can Influence Favorable Cancer Legislation, With Michael Holtz[/caption] Michael Holtz is a 6 1/2 year survivor of Stage IIIB rectal cancer and is the author of the book It's Not Harder Than Cancer. Michael first appeared on this podcast in 2015. You can listen to that interview here. Michael and I discussed the cancer advocacy work he's been doing with the American Cancer Society and as the Tennessee state representative for the American Cancer Society's Cancer Action Network - ACS CAN. In April 2018 the Provision CARES Foundation recognized Michael Holtz as the Patient Advocate of the Year.   Links Mentioned In The Show Michael Holtz' website - http://www.michaelholtzonline.com/ Michael on Facebook - https://facebook.com/michaelandrewholtz/ Michael on Twitter - https://twitter.com/michaelholtz It's Not Harder Than Cancer - Available on Amazon  

Case discussion with Drs. George Blumenschein of MD Anderson and Walter Curran of Emory University, reviewing concerns about risks of aggressive treatment of bulky locally advanced NSCLC and potential management strategies.

Case discussion with Drs. George Blumenschein of MD Anderson and Walter Curran of Emory University, reviewing concerns about risks of aggressive treatment of bulky locally advanced NSCLC and potential management strategies.

ResearchToPractice.com/VPL109 – Case 6: A 68-year-old man with a Stage IIIB squamous cell carcinoma and significant pleural effusion. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPL109 – Case 5: A 66-year-old woman with a Stage IIIB adenocarcinoma of the lung treated with carboplatin/docetaxel/bevacizumab followed by maintenance pemetrexed/bevacizumab. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPL109 – Case 4: A 54-year-old man with a highly symptomatic, Stage IIIB squamous cell carcinoma of the lung. Interviews conducted by Neil Love, MD. Produced by Research To Practice.